Table 1: Demographic data of patients with PsA included between 1995 and 2015 and controls. Presented as n (%) if not specified.
PsA patients (n = 274) | Controls (n = 30) | p-value | |
Age at clinical examination/collection of blood, years (mean ± SD) | 53.6 ± 12.9 | 52.4 ± 17.4 | 0.62 |
Age at investigation of medical record, years (mean ± SD) | 59.5 ± 12.7 | NA | |
PsA disease duration, y (mean ± SD) | 14.0 ± 10.4 | NA | |
Pso disease duration, y (mean ± SD) | 24.2 ± 14.8 | NA | |
Female | 136 (49.6) | 15 (50) | 0.97 |
Variables at clinical examination | |||
- Moderate/high PsA disease activity1 | 87 (32) | NA | |
- Dactylitis | 16 (5.9) | NA | |
Overall disease characteristics | |||
Fulfilling CASPAR-criteria2 | 249 (92) | NA | |
Disease pattern | |||
- Axial disease | 17 (6.2) | NA | |
- Mono-/oligoarthritis | 123 (45) | NA | |
- Polyarthritis (including mutilans) | 130 (48) | NA | |
Axial disease (with or without peripheral disease) | 45 (16) | NA | |
Psoriatic nail disease (ever) | 92 (43) | NA | |
Elevated ESR and/or CRP when active disease | 126 (52) | NA | |
Destructive/deforming disease | 137 (55) | NA | |
bDMARD (ever) | 42 (16) | NA | |
csDMARD (ever) | 89 (45) | NA | |
Rheumatoid factor positivity (ever) | 19 (10) | NA | |
Pso type 1 (onset < 40 years) | 191 (73) | NA |
1Defined as none, Low, Medium, High or Maximal; 2CASPAR criteria [3].